Icahn funds unload stakes in Biogen, Amgen

A few drugmakers might breathe sighs of relief at activist investor Carl Icahn's (photo) latest portfolio update. Icahn's investment vehicles appear to have sold out of Biogen Idec, at which they forced two proxy fights, as well as Amgen and Regeneron Pharmaceuticals. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.